Mylan acquired South African drugmaker’s portfolio of prescription and over-the-counter products in Australia of Aspen Pharmacare for 188m A$ ($130m), through its Aplhapharm subsidiary. In December, Aspen said its wholly owned subsidiary incorporated in Mauritius, Aspen Global Incorporated, and its Australian subsidiaries had entered into a distribution arrangement with Alphapharm, a subsidiary of Mylan in respect of the portfolio commercialized in Australia and New Zealand, where was the point about future possible acquisition. "This divestment is in line with the Group's ongoing portfolio management approach and its stated intention to not only acquire value enhancing products, but to also divest of non-core assets, thereby ensuring enhanced operational focus. The proceeds will be used to reduce Aspen's gearing." Aspen said in a statement.